CYP2C19*2 polymorphism and clopidogrel resistance

CYP2C19*2 polimorfismo y resistencia a clopidogrel

Beuy Joob1* and Viroj Wiwanitkit2
1Sanitation Medical Academic Center, Bangkok, Thailand; 2Department of Tropical Medicine, Hainan Medical University, Hainan, China

LETTER TO EDITOR

Dear Editor,

We read the publication on the “Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico” with a great interest1. Cedillo-Salazar et al. noted that “the presence of the CYP2C19*2 allele is related to resistance to the antplatelet effect of CLO”1. Indeed, the CYP2C19*2 polymorphism can result in molecular change, and this can further result in alteration of phenotypic expression. However, there are also other genetic factors that might relate to clopidogrel resistance. The examples of genetic polymorphisms that might relate to clopidogrel resistance are CES1 gene and MDR1 polymorphisms2,3. Further, a study that addresses the effect of other possible confounding genetic polymorphisms is recommended.

Conflicts of interest

None.

Funding

The present investigation has not received any specific scholarship from the public, commercial, or non-profit agencies.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

References